Nuclide Therapeutics Ltd

Based in the UK, Nuclide Therapeutics Ltd focuses on the development of innovative radiopharmaceutical therapies, providing advanced treatment options for cancer patients through cutting-edge biotechnology. Nuclide Therapeutics Ltd specializes in creating targeted radiopharmaceutical therapies. The company was founded in 2024 and is headquartered in London, UK. It has successfully completed 1 deal, with its most recent deal occurring on September 22, 2025.

This deal involved raising GBP 5 million in Seed funding, all of which has been directed towards enhancing their biotechnology research and pharmaceuticals. Nuclide Therapeutics specializes in the development of innovative radiopharmaceutical therapies, primarily centered around their lead therapeutic, [131I]NTx-11. This product is designed to target specific cancer biomarkers, thereby enhancing the precision of cancer treatment. By integrating the principles of nuclear medicine with advanced biotechnology, Nuclide Therapeutics aims to provide effective treatment alternatives for patients suffering from cancers with limited therapeutic options.

The company's offerings are geared towards healthcare providers and institutions engaged in oncology, with a focus on markets where there is an urgent need for novel cancer therapies. Their products and services are strategically positioned for deployment in regions with advanced healthcare infrastructures and research capabilities, including Europe and North America. The revenue model of Nuclide Therapeutics is structured around partnerships with healthcare institutions and sales to oncology-focused medical facilities. Upon successful completion of clinical trials, the company anticipates generating revenue through direct sales of their flagship product, [131I]NTx-11, to hospitals and specialty clinics that manage cancer treatments.

Transactions may involve upfront fees for initial product purchases followed by additional revenue through ongoing sales as treatment protocols evolve. As the company expands its clinical trial pipeline, further revenue opportunities may arise from collaborations with pharmaceutical partners, aimed at enhancing the therapeutic landscape for oncology care. This structured approach to revenue generation is essential for sustaining ongoing research and development efforts within the company. Nuclide Therapeutics plans to leverage the GBP 5 million raised in Seed funding in September 2025 to support its biotechnology research and pharmaceutical development.

The company is focused on advancing its lead therapeutic, [131I]NTx-11, with plans for potential new products to be launched as clinical trials progress. Additionally, Nuclide Therapeutics aims to expand its presence in both European and North American markets, targeting regions with robust healthcare infrastructures by mid-2026.